The eEF1A proteins: At the crossroads of oncogenesis, apoptosis, and viral infections

Frontiers in Oncology

Volumn 5, Issue APR, 2015, Pages

  Abbas, Wasim ^a   Kumar, Amit ^b   Herbein, Georges ^b  

^a LAHORE UNIVERSITY OF MANAGEMENT SCIENCES   (Pakistan)

^b Hôpital Saint Jacques   (France)

Author keywords

Apoptosis; Cancer; eEF1A; HIV; Virus

Indexed keywords

ACTIN; CHAPERONE; INITIATION FACTOR 1A; PHOSPHOLIPID; PROTEIN KINASE B; RESVERATROL;

APOPTOSIS; BREAST CANCER; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL TRIAL (TOPIC); CYTOSKELETON; GENE EXPRESSION; GENE SILENCING; HUMAN; IMMUNE DEFICIENCY; LUNG CANCER; MUSCLE DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROTEIN EXPRESSION; REVIEW; UPREGULATION; VIRUS INFECTION; VIRUS REPLICATION;

EID: 84934277859     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00075     Document Type: Review

References (112)

1. Thornton S, Anand N, Purcell D, Lee J. Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med (Berl) (2003) 81(9):536-48. doi:10.1007/s00109-003-0461-8
2. Li GW, Xie XS. Central dogma at the single-molecule level in living cells. Nature (2011) 475(7356):308-15. doi:10.1038/nature10315
3. Garner AL, Janda KD. Protein-protein interactions and cancer: targeting the central dogma. Curr Top Med Chem (2011) 11(3):258-80. doi:10.2174/156802611794072614
4. Caraglia M, Budillon A, Vitale G, Lupoli G, Tagliaferri P, Abbruzzese A. Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. Eur J Biochem (2000) 267(13):3919-36. doi:10.1046/j.1432-1327.2000.01465.x
5. Clemens MJ. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene (2004) 23(18):3180-8. doi:10.1038/sj.onc.1207544
6. Browne GJ, Proud CG. Regulation of peptide-chain elongation in mammalian cells. Eur J Biochem (2002) 269(22):5360-8. doi:10.1046/j.1432-1033.2002.03290.x
7. Soares DC, Barlow PN, Newbery HJ, Porteous DJ, Abbott CM. Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of sequence variation and potential differences in phosphorylation. PLoS One (2009) 4(7):e6315. doi:10.1371/journal.pone.0006315
8. Panwar D, Rawal L, Ali S. Molecular docking uncovers TSPY binds more efficiently with eEF1A2 compared to eEF1A1. J Biomol Struct Dyn (2014) 9:1-12. doi:10.1080/07391102.2014.952664
9. Yaremchuk A, Shalak VF, Novosylna OV, Negrutskii BS, Crepin T, El'skaya AV, et al. Purification, crystallization and preliminary X-ray crystallographic analysis of mammalian translation elongation factor eEF1A2. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 68(Pt 3):295-7. doi:10.1107/S1744309112000243
10. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res (2003) 31(13):3381-5. doi:10.1093/nar/gkg520
11. Knudsen SM, Frydenberg J, Clark BF, Leffers H. Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha. Eur J Biochem (1993) 215(3):549-54. doi:10.1111/j.1432-1033.1993.tb18064.x
12. Sasikumar AN, Perez WB, Kinzy TG. The many roles of the eukaryotic elongation factor 1 complex. Wiley Interdiscip Rev RNA. (2012) 3(4):543-55. doi:10.1002/wrna.1118
13. Doig J, Griffiths LA, Peberdy D, Dharmasaroja P, Vera M, Davies FJ, et al. In vivo characterization of the role of tissue-specific translation elongation factor 1A2 in protein synthesis reveals insights into muscle atrophy. FEBS J (2013) 280(24):6528-40. doi:10.1111/febs.12554
14. Kahns S, Lund A, Kristensen P, Knudsen CR, Clark BF, Cavallius J, et al. The elongation factor 1 A-2 isoform from rabbit: cloning of the cDNA and characterization of the protein. Nucleic Acids Res (1998) 26(8):1884-90. doi:10.1093/nar/26.8.1884
15. Lund A, Knudsen SM, Vissing H, Clark B, Tommerup N. Assignment of human elongation factor 1alpha genes: eEF1A maps to chromosome 6q14 and eEF1A2 to 20q13.3. Genomics (1996) 36(2):359-61. doi:10.1006/geno.1996.0475
16. Soares DC, Abbott CM. Highly homologous eEF1A1 and eEF1A2 exhibit differential post-translational modification with significant enrichment around localised sites of sequence variation. Biol Direct (2013) 8:29. doi:10.1186/1745-6150-8-29
17. Sanges C, Scheuermann C, Zahedi RP, Sickmann A, Lamberti A, Migliaccio N, et al. Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells. Cell Death Dis (2012) 3:e276. doi:10.1038/cddis.2012.16
18. Khacho M, Mekhail K, Pilon-Larose K, Pause A, Cote J, Lee S. eEF1A is a novel component of the mammalian nuclear protein export machinery. Mol Biol Cell (2008) 19(12):5296-308. doi:10.1091/mbc.E08-06-0562
19. Bischoff C, Kahns S, Lund A, Jorgensen HF, Praestegaard M, Clark BF, et al. The human elongation factor 1 A-2 gene (EEF1A2): complete sequence and characterization of gene structure and promoter activity. Genomics (2000) 68(1):63-70. doi:10.1006/geno.2000.6271
20. Lamberti A, Caraglia M, Longo O, Marra M, Abbruzzese A, Arcari P. The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article. Amino Acids (2004) 26(4):443-8. doi:10.1007/s00726-004-0088-2
21. Gandin V, Gutierrez GJ, Brill LM, Varsano T, Feng Y, Aza-Blanc P, et al. Degradation of newly synthesized polypeptides by ribosome-associated RACK1/c-Jun N-terminal kinase/eukaryotic elongation factor 1A2 complex. Mol Cell Biol (2013) 33(13):2510-26. doi:10.1128/MCB.01362-12
22. Veeramah KR, Johnstone L, Karafet TM, Wolf D, Sprissler R, Salogiannis J, et al. Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. Epilepsia (2013) 54(7):1270-81. doi:10.1111/epi.12201
23. Miura P, Coriati A, Belanger G, De RY, Lee J, Kothary R, et al. The utrophin A 5'-UTR drives cap-independent translation exclusively in skeletal muscles of transgenic mice and interacts with eEF1A2. Hum Mol Genet (2010) 19(7):1211-20. doi:10.1093/hmg/ddp591
24. Hinestrosa MC, Dickersin K, Klein P, Mayer M, Noss K, Slamon D, et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer (2007) 7(4):309-15. doi:10.1038/nrc2144
25. Tomlinson VA, Newbery HJ, Wray NR, Jackson J, Larionov A, Miller WR, et al. Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer (2005) 5:113. doi:10.1186/1471-2407-5-113
26. Yao N, Chen CY, Wu CY, Motonishi K, Kung HJ, Lam KS. Novel flavonoids with antiproliferative activities against breast cancer cells. J Med Chem (2011) 54(13):4339-49. doi:10.1021/jm101440r
27. Amiri A, Noei F, Jeganathan S, Kulkarni G, Pinke DE, Lee JM. eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene (2007) 26(21):3027-40. doi:10.1038/sj.onc.1210101
28. Pecorari L, Marin O, Silvestri C, Candini O, Rossi E, Guerzoni C, et al. Elongation factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility. Mol Cancer (2009) 8:58. doi:10.1186/1476-4598-8-58
29. Li Z, Qi CF, Shin DM, Zingone A, Newbery HJ, Kovalchuk AL, et al. eEF1A2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas. PLoS One (2010) 5(5):e10755. doi:10.1371/journal.pone.0010755
30. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem (1998) 67:481-507. doi:10.1146/annurev.biochem.67.1.481
31. Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer (2010) 10(5):342-52. doi:10.1038/nrc2842
32. Balla A, Balla T. Phosphatidylinositol 4-kinases: old enzymes with emerging functions. Trends Cell Biol (2006) 16(7):351-61. doi:10.1016/j.tcb.2006.05.003
33. Carpenter CL, Cantley LC. Phosphoinositide kinases. Curr Opin Cell Biol (1996) 8(2):153-8. doi:10.1016/S0955-0674(96)80060-3
34. Jeganathan S, Lee JM. Binding of elongation factor eEF1A2 to phosphatidylinositol 4-kinase beta stimulates lipid kinase activity and phosphatidylinositol 4-phosphate generation. J Biol Chem (2007) 282(1):372-80. doi:10.1074/jbc.M602955200
35. Pinke DE, Lee JM. The lipid kinase PI4KIIIbeta and the eEF1A2 oncogene co-operate to disrupt three-dimensional in vitro acinar morphogenesis. Exp Cell Res (2011) 317(17):2503-11. doi:10.1016/j.yexcr.2011.08.002
36. Jeganathan S, Morrow A, Amiri A, Lee JM. Eukaryotic elongation factor 1A2 cooperates with phosphatidylinositol-4 kinase III beta to stimulate production of filopodia through increased phosphatidylinositol-4,5 bisphosphate generation. Mol Cell Biol (2008) 28(14):4549-61. doi:10.1128/MCB.00150-08
37. Vislovukh A, Kratassiouk G, Porto E, Gralievska N, Beldiman C, Pinna G, et al. Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744. Br J Cancer (2013) 108(11):2304-11. doi:10.1038/bjc.2013.243
38. Lee MH, Choi BY, Cho YY, Lee SY, Huang Z, Kundu JK, et al. Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction. J Cell Sci (2013) 126(Pt 8):1744-52. doi:10.1242/jcs.113613
39. Kulkarni G, Turbin DA, Amiri A, Jeganathan S, Andrade-Navarro MA, Wu TD, et al. Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer. Breast Cancer Res Treat (2007) 102(1):31-41. doi:10.1007/s10549-006-9315-8
40. Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, et al. Protein elongation factor eEF1A2 is a putative oncogene in ovarian cancer. Nat Genet (2002) 31(3):301-5. doi:10.1038/ng904
41. Zhu H, Lam DC, Han KC, Tin VP, Suen WS, Wang E, et al. High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines. Cancer Lett (2007) 245(1-2):303-14. doi:10.1016/j.canlet.2006.01.020
42. Li R, Wang H, Bekele BN, Yin Z, Caraway NP, Katz RL, et al. Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene (2006) 25(18):2628-35. doi:10.1038/sj.onc.1209289
43. Grassi G, Scaggiante B, Farra R, Dapas B, Agostini F, Baiz D, et al. The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade. Biochimie (2007) 89(12):1544-52. doi:10.1016/j.biochi.2007.07.007
44. Schlaeger C, Longerich T, Schiller C, Bewerunge P, Mehrabi A, Toedt G, et al. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology (2008) 47(2):511-20. doi:10.1002/hep.22033
45. Tanner MM, Tirkkonen M, Kallioniemi A, Holli K, Collins C, Kowbel D, et al. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res (1995) 1(12):1455-61.
46. Edmonds BT, Wyckoff J, Yeung YG, Wang Y, Stanley ER, Jones J, et al. Elongation factor-1 alpha is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma. J Cell Sci (1996) 109(Pt 11):2705-14.
47. Joseph P, O'Kernick CM, Othumpangat S, Lei YX, Yuan BZ, Ong TM. Expression profile of eukaryotic translation factors in human cancer tissues and cell lines. Mol Carcinog (2004) 40(3):171-9. doi:10.1002/mc.20033
48. Sun Y, Du C, Wang B, Zhang Y, Liu X, Ren G. Up-regulation of eEF1A2 promotes proliferation and inhibits apoptosis in prostate cancer. Biochem Biophys Res Commun (2014) 450(1):1-6. doi:10.1016/j.bbrc.2014.05.045
49. Rehman I, Evans CA, Glen A, Cross SS, Eaton CL, Down J, et al. iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer. PLoS One (2012) 7(2):e30885. doi:10.1371/journal.pone.0030885
50. Tatsuka M, Mitsui H, Wada M, Nagata A, Nojima H, Okayama H. Elongation factor-1 alpha gene determines susceptibility to transformation. Nature (1992) 359(6393):333-6. doi:10.1038/359333a0
51. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003) 3(7):502-16. doi:10.1038/nrc1123
52. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer (2005) 5(5):355-66. doi:10.1038/nrc1611
53. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet (2009) 374(9698):1371-82. doi:10.1016/S0140-6736(09)61338-6
54. Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res (2012) 31:14. doi:10.1186/1756-9966-31-14
55. Tomlinson VA, Newbery HJ, Bergmann JH, Boyd J, Scott D, Wray NR, et al. Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the eEF1A2 locus. Br J Cancer (2007) 96(10):1613-20. doi:10.1038/sj.bjc.6603748
56. Pinke DE, Kalloger SE, Francetic T, Huntsman DG, Lee JM. The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecol Oncol (2008) 108(3):561-8. doi:10.1016/j.ygyno.2007.11.019
57. Lee MH, Surh YJ. eEF1A2 as a putative oncogene. Ann N Y Acad Sci (2009) 1171:87-93. doi:10.1111/j.1749-6632.2009.04909.x
58. Sun Y, Wong N, Guan Y, Salamanca CM, Cheng JC, Lee JM, et al. The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas. Int J Cancer (2008) 123(8):1761-9. doi:10.1002/ijc.23708
59. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett (2008) 269(2):243-61. doi:10.1016/j.canlet.2008.03.057
60. Wendling D, Abbas W, Godfrin-Valnet M, Guillot X, Khan KA, Cedoz JP, et al. Resveratrol, a sirtuin 1 activator, increases IL-6 production by peripheral blood mononuclear cells of patients with knee osteoarthritis. Clin Epigenetics (2013) 5(1):10. doi:10.1186/1868-7083-5-10
61. Lee MH, Choi BY, Kundu JK, Shin YK, Na HK, Surh YJ. Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res (2009) 69(18):7449-58. doi:10.1158/0008-5472.CAN-09-1266
62. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin (2010) 60(5):277-300. doi:10.3322/caac.20073
63. Marugame T, Hirabayashi Y. Comparison of time trends in lung cancer mortality (1990-2006) in the world, from the WHO mortality database. Jpn J Clin Oncol (2009) 39(10):696-7. doi:10.1093/jjco/hyp138
64. Lam DC, Girard L, Suen WS, Chung LP, Tin VP, Lam WK, et al. Establishment and expression profiling of new lung cancer cell lines from Chinese smokers and lifetime never-smokers. J Thorac Oncol (2006) 1(9):932-42. doi:10.1097/01243894-200611000-00003
65. Effendi K, Sakamoto M. Molecular pathology in early hepatocarcinogenesis. Oncology (2010) 78(2):157-60. doi:10.1159/000312658
66. Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther (2010) 10(4):507-19. doi:10.1586/era.10.24
67. Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, et al. eEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology (2014) 59(5):1886-99. doi:10.1002/hep.26954
68. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 6(9):674-87. doi:10.1038/nrc1934
69. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet (2004) 363(9414):1049-57. doi:10.1016/S0140-6736(04)15841-8
70. Shaib YH, Davila JA, El-Serag HB. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther (2006) 24(1):87-94. doi:10.1111/j.1365-2036.2006.02961.x
71. Cao H, Zhu Q, Huang J, Li B, Zhang S, Yao W, et al. Regulation and functional role of eEF1A2 in pancreatic carcinoma. Biochem Biophys Res Commun (2009) 380(1):11-6. doi:10.1016/j.bbrc.2008.12.171
72. Xu C, Hu DM, Zhu Q. eEF1A2 promotes cell migration, invasion and metastasis in pancreatic cancer by upregulating MMP-9 expression through Akt activation. Clin Exp Metastasis (2013) 30(7):933-44. doi:10.1007/s10585-013-9593-6
73. Duanmin H, Chao X, Qi Z. eEF1A2 protein expression correlates with lymph node metastasis and decreased survival in pancreatic ductal adenocarcinoma. Hepatogastroenterology (2013) 60(124):870-5. doi:10.5754/hge12869
74. Fan Y, Bergmann A. Apoptosis-induced compensatory proliferation. The cell is dead. Long live the cell! Trends Cell Biol (2008) 18(10):467-73. doi:10.1016/j.tcb.2008.08.001
75. Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol (2007) 19(5):488-96. doi:10.1016/j.coi.2007.05.004
76. Chang R, Wang E. Mouse translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress. J Cell Biochem (2007) 100(2):267-78. doi:10.1002/jcb.20969
77. Abbas W, Khan KA, Kumar A, Tripathy MK, Dichamp I, Keita M, et al. Blockade of BFA-mediated apoptosis in macrophages by the HIV-1 Nef protein. Cell Death Dis (2014) 5:e1080. doi:10.1038/cddis.2014.16
78. Chen E, Proestou G, Bourbeau D, Wang E. Rapid up-regulation of peptide elongation factor EF-1alpha protein levels is an immediate early event during oxidative stress-induced apoptosis. Exp Cell Res (2000) 259(1):140-8. doi:10.1006/excr.2000.4952
79. Day AM, Brown JD, Taylor SR, Rand JD, Morgan BA, Veal EA. Inactivation of a peroxiredoxin by hydrogen peroxide is critical for thioredoxin-mediated repair of oxidized proteins and cell survival. Mol Cell (2012) 45(3):398-408. doi:10.1016/j.molcel.2011.11.027
80. Talapatra S, Wagner JD, Thompson CB. Elongation factor-1 alpha is a selective regulator of growth factor withdrawal and ER stress-induced apoptosis. Cell Death Differ (2002) 9(8):856-61. doi:10.1038/sj.cdd.4401078
81. Newbery HJ, Loh DH, O'Donoghue JE, Tomlinson VA, Chau YY, Boyd JA, et al. Translation elongation factor eEF1A2 is essential for post-weaning survival in mice. J Biol Chem (2007) 282(39):28951-9. doi:10.1074/jbc.M703962200
82. Chambers DM, Peters J, Abbott CM. The lethal mutation of the mouse wasted (wst) is a deletion that abolishes expression of a tissue-specific isoform of translation elongation factor 1alpha, encoded by the Eef1a2 gene. Proc Natl Acad Sci U S A (1998) 95(8):4463-8. doi:10.1073/pnas.95.8.4463
83. Potter M, Bernstein A, Lee JM. The wst gene regulates multiple forms of thymocyte apoptosis. Cell Immunol (1998) 188(2):111-7. doi:10.1006/cimm.1998.1346
84. Nakajima J, Okamoto N, Tohyama J, Kato M, Arai H, Funahashi O, et al. De novo eEF1A2 mutations in patients with characteristic facial features, intellectual disability, autistic behaviors and epilepsy. Clin Genet (2015) 87(4):356-61. doi:10.1111/cge.12394
85. Ruest LB, Marcotte R, Wang E. Peptide elongation factor eEF1A-2/S1 expression in cultured differentiated myotubes and its protective effect against caspase-3-mediated apoptosis. J Biol Chem (2002) 277(7):5418-25. doi:10.1074/jbc.M110685200
86. Abbott CM, Newbery HJ, Squires CE, Brownstein D, Griffiths LA, Soares DC. eEF1A2 and neuronal degeneration. Biochem Soc Trans (2009) 37(Pt 6):1293-7. doi:10.1042/BST0371293
87. Li D, Wei T, Abbott CM, Harrich D. The unexpected roles of eukaryotic translation elongation factors in RNA virus replication and pathogenesis. Microbiol Mol Biol Rev (2013) 77(2):253-66. doi:10.1128/MMBR.00059-12
88. Cimarelli A, Luban J. Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. J Virol (1999) 73(7):5388-401.
89. Ott DE, Coren LV, Johnson DG, Kane BP, Sowder RC, Kim YD, et al. Actin-binding cellular proteins inside human immunodeficiency virus type 1. Virology (2000) 266(1):42-51. doi:10.1006/viro.1999.0075
90. Warren K, Wei T, Li D, Qin F, Warrilow D, Lin MH, et al. Eukaryotic elongation factor 1 complex subunits are critical HIV-1 reverse transcription cofactors. Proc Natl Acad Sci U S A (2012) 109(24):9587-92. doi:10.1073/pnas.1204673109
91. Allouch A, Cereseto A. Identification of cellular factors binding to acetylated HIV-1 integrase. Amino Acids (2011) 41(5):1137-45. doi:10.1007/s00726-009-0444-3
92. Parissi V, Calmels C, De Soultrait VR, Caumont A, Fournier M, Chaignepain S, et al. Functional interactions of human immunodeficiency virus type 1 integrase with human and yeast HSP60. J Virol (2001) 75(23):11344-53. doi:10.1128/JVI.75.23.11344-11353.2001
93. Tan R, Patni H, Tandon P, Luan L, Sharma B, Salhan D, et al. Nef interaction with actin compromises human podocyte actin cytoskeletal integrity. Exp Mol Pathol (2013) 94(1):51-7. doi:10.1016/j.yexmp.2012.06.001
94. Wu-Baer F, Lane WS, Gaynor RB. Identification of a group of cellular cofactors that stimulate the binding of RNA polymerase II and TRP-185 to human immunodeficiency virus 1 TAR RNA. J Biol Chem (1996) 271(8):4201-8. doi:10.1074/jbc.271.8.4201
95. Abbas W, Dichamp I, Herbein G. The HIV-1 Nef protein interacts with two components of the 40S small ribosomal subunit, the RPS10 protein and the 18S rRNA. Virol J (2012) 9:103. doi:10.1186/1743-422X-9-103
96. Xiao H, Neuveut C, Benkirane M, Jeang KT. Interaction of the second coding exon of Tat with human EF-1 delta delineates a mechanism for HIV-1-mediated shut-off of host mRNA translation. Biochem Biophys Res Commun (1998) 244(2):384-9. doi:10.1006/bbrc.1998.8274
97. Lin WS, Jiao BY, Wu YL, Chen WN, Lin X. Hepatitis B virus X protein blocks filamentous actin bundles by interaction with eukaryotic translation elongation factor 1 alpha 1. J Med Virol (2012) 84(6):871-7. doi:10.1002/jmv.23283
98. Sikora D, Greco-Stewart VS, Miron P, Pelchat M. The hepatitis delta virus RNA genome interacts with eEF1A1, p54(nrb), hnRNP-L, GAPDH and ASF/SF2. Virology (2009) 390(1):71-8. doi:10.1016/j.virol.2009.04.022
99. Yue J, Shukla R, Accardi R, Zanella-Cleon I, Siouda M, Cros MP, et al. Cutaneous human papillomavirus type 38 E7 regulates actin cytoskeleton structure for increasing cell proliferation through CK2 and the eukaryotic elongation factor 1A. J Virol (2011) 85(17):8477-94. doi:10.1128/JVI.02561-10
100. Blackwell JL, Brinton MA. Translation elongation factor-1 alpha interacts with the 3' stem-loop region of West Nile virus genomic RNA. J Virol (1997) 71(9):6433-44.
101. Davis WG, Blackwell JL, Shi PY, Brinton MA. Interaction between the cellular protein eEF1A and the 3'-terminal stem-loop of West Nile virus genomic RNA facilitates viral minus-strand RNA synthesis. J Virol (2007) 81(18):10172-87. doi:10.1128/JVI.00531-07
102. Carr JM, Kua T, Clarke JN, Calvert JK, Zebol JR, Beard MR, et al. Reduced sphingosine kinase 1 activity in dengue virus type-2 infected cells can be mediated by the 3' untranslated region of dengue virus type-2 RNA. J Gen Virol (2013) 94(Pt 11):2437-48. doi:10.1099/vir.0.055616-0
103. Zhang X, Shi H, Chen J, Shi D, Li C, Feng L. EF1A interacting with nucleocapsid protein of transmissible gastroenteritis coronavirus and plays a role in virus replication. Vet Microbiol (2014) 172(3-4):443-8. doi:10.1016/j.vetmic.2014.05.034
104. Moerdyk-Schauwecker M, Hwang SI, Grdzelishvili VZ. Analysis of virion associated host proteins in vesicular stomatitis virus using a proteomics approach. Virol J (2009) 6:166. doi:10.1186/1743-422X-6-166
105. Chung CS, Chen CH, Ho MY, Huang CY, Liao CL, Chang W. Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J Virol (2006) 80(5):2127-40. doi:10.1128/JVI.80.5.2127-2140.2006
106. Resch W, Hixson KK, Moore RJ, Lipton MS, Moss B. Protein composition of the vaccinia virus mature virion. Virology (2007) 358(1):233-47. doi:10.1016/j.virol.2006.08.025
107. Kattenhorn LM, Mills R, Wagner M, Lomsadze A, Makeev V, Borodovsky M, et al. Identification of proteins associated with murine cytomegalovirus virions. J Virol (2004) 78(20):11187-97. doi:10.1128/JVI.78.20.11187-11197.2004
108. Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, Pasa-Tolic L, et al. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol (2004) 78(20):10960-6. doi:10.1128/JVI.78.23.13395.2004
109. Neuman BW, Joseph JS, Saikatendu KS, Serrano P, Chatterjee A, Johnson MA, et al. Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3. J Virol (2008) 82(11):5279-94. doi:10.1128/JVI.02631-07
110. Tang H, Oishi N, Kaneko S, Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci (2006) 97(10):977-83. doi:10.1111/j.1349-7006.2006.00299.x
111. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes (2010) 40(1):1-13. doi:10.1007/s11262-009-0412-8
112. Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JW Jr, et al. Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol (2006) 80(18):9039-52. doi:10.1128/JVI.01013-06